Equities Analysts Offer Predictions for Turning Point Therapeutics’ Q1 2019 Earnings (TPTX)

Share on StockTwits

Turning Point Therapeutics (NASDAQ:TPTX) – Stock analysts at Svb Leerink issued their Q1 2019 EPS estimates for Turning Point Therapeutics in a research report issued to clients and investors on Monday, May 13th. Svb Leerink analyst A. Berens expects that the company will earn ($0.69) per share for the quarter. Svb Leerink currently has a “Outperform” rating and a $42.00 target price on the stock. Svb Leerink also issued estimates for Turning Point Therapeutics’ Q2 2019 earnings at ($0.45) EPS, Q3 2019 earnings at ($0.60) EPS, Q4 2019 earnings at ($0.74) EPS, FY2019 earnings at ($2.44) EPS, FY2020 earnings at ($3.54) EPS, FY2021 earnings at ($4.64) EPS, FY2022 earnings at ($3.43) EPS and FY2023 earnings at ($0.33) EPS.

TPTX has been the subject of a number of other research reports. Canaccord Genuity assumed coverage on shares of Turning Point Therapeutics in a research note on Monday, May 13th. They set a “buy” rating and a $48.00 target price for the company. Wells Fargo & Co assumed coverage on shares of Turning Point Therapeutics in a research note on Monday, May 13th. They set an “outperform” rating and a $53.00 target price for the company. Goldman Sachs Group assumed coverage on shares of Turning Point Therapeutics in a research note on Monday, May 13th. They set a “buy” rating and a $50.00 target price for the company. Royal Bank of Canada assumed coverage on shares of Turning Point Therapeutics in a research note on Monday, May 13th. They set an “outperform” rating and a $48.00 target price for the company. Finally, Leerink Swann assumed coverage on shares of Turning Point Therapeutics in a research note on Monday, May 13th. They set an “outperform” rating and a $42.00 target price for the company. Six analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus price target of $47.17.

Shares of NASDAQ:TPTX opened at $34.27 on Thursday. Turning Point Therapeutics has a 12-month low of $24.21 and a 12-month high of $38.00.

In other Turning Point Therapeutics news, major shareholder Cormorant Asset Management, Lp acquired 400,000 shares of Turning Point Therapeutics stock in a transaction that occurred on Monday, April 22nd. The stock was acquired at an average price of $18.00 per share, with a total value of $7,200,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Athena Countouriotis acquired 12,000 shares of Turning Point Therapeutics stock in a transaction that occurred on Monday, April 22nd. The stock was acquired at an average cost of $18.00 per share, with a total value of $216,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 774,800 shares of company stock valued at $13,946,400.

About Turning Point Therapeutics

Turning Point Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.

Further Reading: What is a Lock-Up Period?

Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Analysts Expect Yogaworks Inc  to Post -$0.19 Earnings Per Share
Zacks: Analysts Expect Yogaworks Inc to Post -$0.19 Earnings Per Share
Zacks: Brokerages Anticipate Ranger Energy Services Inc  to Post $0.23 EPS
Zacks: Brokerages Anticipate Ranger Energy Services Inc to Post $0.23 EPS
$0.47 Earnings Per Share Expected for Service Co. International  This Quarter
$0.47 Earnings Per Share Expected for Service Co. International This Quarter
Capital Southwest Co.  Expected to Announce Earnings of $0.41 Per Share
Capital Southwest Co. Expected to Announce Earnings of $0.41 Per Share
Analysts Anticipate SITE Centers Corp.  Will Post Earnings of $0.28 Per Share
Analysts Anticipate SITE Centers Corp. Will Post Earnings of $0.28 Per Share
Zacks: Analysts Anticipate Ingevity Corp  Will Announce Earnings of $1.35 Per Share
Zacks: Analysts Anticipate Ingevity Corp Will Announce Earnings of $1.35 Per Share


© 2006-2019 Ticker Report